[1] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet,2018,391:1301-1314.
[2] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版).中华肝脏病杂志,2020,28:112-128.
[3] Rajakannu M, Cherqui D, Ciacio O, et al. Liver stiffness measurement by transient elastography predicts late posthepatectomy outcomes in patients undergoing resection for hepatocellular carcinoma. Surgery, 2017,162:766-774.
[4] Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology,73(Suppl 1):137-149.
[5] Uhlig J, Sellers CM, Stein SM, et al. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database. Eur Radiol,2019,29:2679-2689.
[6] Namiki I, Kiyoshi H, Yujiro N, et al. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). J Clin Oncol,2019:4002-4002.
[7] Bhangui P, Allard MA, Vibert E, et al. Salvage Versus Primary Liver Transplantation for Early Hepatocellular Carcinoma: Do Both Strategies Yield Similar Outcomes? Ann Surg,2016,264:155-163.
[8] Yu J, Yu XL, Han ZY, et al. Percutaneous cooled-probe microwave versus radiofrequency ablation in early-stage hepatocellular carcinoma: a phase III randomized controlled trial. Gut, 2017,66:1172-1173.
[9] Durand-Labrunie J, Baumann AS, Ayav A, et al. Curative Irradiation Treatment of Hepatocellular Carcinoma: A Multicenter Phase 2 Trial. Int J Radiat Oncol Biol Phys,2020,107:116-125.
[10] Kim N, Cheng J, Jung I, et al. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma. J Hepatol,2020,73:121-129.
[11] Brown KT, Do RK, Gonen M, et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared with Embolization With Microspheres Alone. J Clin Oncol,2016,34:2046-2053.
[12] Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology,2018,287:1050-1058.
[13] Kudo M, Arizumi T, Ueshima K, et al. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). Dig Dis,2015,33:751-758.
[14] Tavernier J, Fagnoni P, Chabrot P, et al. Comparison of two transarterial chemoembolization strategies for hepatocellular carcinoma. Anticancer Res,2014,34:7247-7253.
[15] Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology,2014,87 Suppl 1:22-31.
[16] Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol,2019,16:617-630.
[17] Allard MA, Sebagh M, Ruiz A, et al. Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation? J Hepatol,2015,63:83-92.
[18] Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology,2015,61:1968-1977.
[19] Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med,2020,382:1894-1905.
[20] Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer,2019,8:299-311.
[21] Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol,2017,66:545-551. |
